Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Novo Nordisk A/S — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.17, while Novo Nordisk A/S trades at $46.05 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals.
| KOLD | NVO | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $63.98 |
52-Week Low | $13.58 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.035, down 2.11% today, with technical indicators showing a bullish bias despite recent weakness. The stock faces strong resistance at $29-$30 levels while finding support at $28. Natural gas market volatility continues to drive price action, with weather forecasts and LNG export flows being key near-term catalysts. Recent news highlights steady natural gas futures trading amid mixed demand signals.
The outlook remains tactical given KOLD's leveraged exposure to natural gas price movements. Upside potential exists if weather-driven demand strengthens, but risks include production increases and storage levels. Investors should monitor EIA storage reports and global LNG demand trends for directional cues in this volatile energy sector ETF.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
